Spectral AI Holds Annual Stockholders Meeting

Spectral AI ( (MDAI) ) has provided an update.

On May 28, 2025, Spectral AI held its Annual Meeting of Stockholders, where 60.8% of eligible shares were represented. During the meeting, six directors were elected to the Board, and the appointment of KPMG LLP as the independent registered public accounting firm for 2025 was ratified. This meeting underscores the company’s commitment to maintaining strong governance and financial oversight, which is crucial for its ongoing efforts to revolutionize wound care diagnostics.

The most recent analyst rating on (MDAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Spectral AI stock, see the MDAI Stock Forecast page.

Spark’s Take on MDAI Stock

According to Spark, TipRanks’ AI Analyst, MDAI is a Neutral.

Spectral AI shows significant revenue growth and strategic technological developments, yet faces substantial financial challenges with negative profitability and high leverage. Technical indicators suggest bearish momentum, and the valuation appears unattractive due to the negative P/E ratio. The earnings call presents a mixed outlook, highlighting achievements but also projecting revenue declines, contributing to a cautious overall assessment.

To see Spark’s full report on MDAI stock, click here.

More about Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company specializing in medical diagnostics aimed at enhancing treatment decisions in wound care, particularly for burn patients. The company is developing the DeepView® System, a predictive device designed to provide clinicians with immediate assessments of burn wounds’ healing potential, thereby improving patient outcomes and reducing healthcare costs.

Average Trading Volume: 314,046

Technical Sentiment Signal: Sell

Current Market Cap: $37.85M

For detailed information about MDAI stock, go to TipRanks’ Stock Analysis page.